Trastuzumab in combination with S-1/CDDP in HER2-positive advanced gastric cancer: a phase II trial.

Trial Profile

Trastuzumab in combination with S-1/CDDP in HER2-positive advanced gastric cancer: a phase II trial.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 May 2016

At a glance

  • Drugs Cisplatin (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Trastuzumab (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Nov 2013 Planned End Date changed from 31 Dec 2014 to 30 Jun 2016 as reported by University Hospital Medical Information Network - Japan record.
    • 17 Jun 2013 Planned end date added (31 Dec 2014) as reported by University Hospital Medical Information Network - Japan record.
    • 27 Jul 2012 Additional lead trial centers identified as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top